Table 4.
Univariate analysis of overall survival and immune parameter in non-induction chemotherapy patients (N = 164)
| Marker | Tumor | Stroma | ||||||
|---|---|---|---|---|---|---|---|---|
| N (%) | Median OS | 95%CI | P- value* | N (%) | Median OS | 95%CI | P-value* | |
| CD3 | 0.24 | |||||||
| Low | 38 (25) | 14.4 | (9.4, 28.8) | 101 (66) | 15.4 | (12.3, 19.3) | 0.65 | |
| High | 115 (75) | 15.4 | (12.3, 19.2) | 52 (34) | 15.2 | (11.4, 20.9) | ||
| CD4 | 0.13 | |||||||
| Low | 87 (56) | 14.7 | (9.8, 18.9) | 19 (12) | 15.0 | (7.4, 22.0) | 0.14 | |
| High | 68 (44) | 16.1 | (12.4, 23.8) | 135 (88) | 16.1 | (12.5, 19.2) | ||
| CD8 | 0.17 | |||||||
| Low | 63 (41) | 14.7 | (12.0, 19.8) | 63 (41) | 18.9 | (14.7, 22.0) | 0.24 | |
| High | 91 (59) | 16.1 | (11.4, 19.3) | 91 (59) | 14.5 | (11.4, 17.0) | ||
| CD45RO | 0.9 | |||||||
| Low | 70 (60) | 15.4 | (12.4, 23.4) | 103 (87) | 15.0 | (12.4, 18.9) | 0.71 | |
| High | 46 (40) | 15.0 | (9.5, 20.9) | 15 (13) | 16.3 | (8.2, 26.6) | ||
| CD20 | 0.18 | |||||||
| Low | 97 (63) | 15.0 | (10.6, 18.1) | 67 (44) | 15.0 | (10.6, 18.9) | 0.22 | |
| High | 57 (37) | 16.9 | (11.4, 23.8) | 85 (56) | 16.3 | (12.4, 20.9) | ||
| FoxP3 | 0.75 | |||||||
| Low | 97 (63) | 16.1 | (12.5, 19.9) | 101 (65) | 15.0 | (12.3, 19.1) | 0.51 | |
| High | 58 (37) | 14.5 | (9.4, 19.4) | 54 (35) | 15.4 | (10.5, 20.9) | ||
| CD68 | 0.79 | |||||||
| Low | 125 (81) | 15.2 | (12.3, 19.2) | 15 (10) | 23.4 | (16.2, 113.8) | 0.03 | |
| High | 30 (19) | 15.0 | (8.1, 23.4) | 139 (90) | 15.0 | (12.3, 17.5) | ||
| CD163 | 0.26 | |||||||
| Low | 81 (54) | 18.9 | (14.7, 22.0) | 94 (67) | 17.5 | (14.5, 22.0) | 0.041 | |
| High | 70 (46) | 12.0 | (8.8, 16.9) | 46 (33) | 11.0 | (8.7, 16.1) | ||
| IL-7R | 0.006 | |||||||
| Low | 80 (52) | 19.1 | (15.2, 28.1) | † | ||||
| High | 75 (48) | 12.3 | (9.0, 16.2) | |||||
| IL-12Rβ2 | 0.27 | |||||||
| Low | 90 (78) | 15.2 | (12.3, 19.1) | † | ||||
| High | 26 (22) | 14.7 | (8.2, 38.0) | |||||
| CCR7 | 0.19 | |||||||
| Low | 94 (80) | 14.9 | (12.0, 17.6) | † | ||||
| High | 24 (20) | 28.1 | (9.5, 45.5) | |||||
| CXCL12 | 0.68 | |||||||
| Low | 40 (34) | 14.0 | (9.8, 18.1) | † | ||||
| High | 77 (66) | 16.3 | (14.5, 22.0) | |||||
| CXCR4 | 0.67 | |||||||
| Low | 82 (72) | 15.0 | (12.3, 19.1) | † | ||||
| High | 32 (28) | 16.2 | (8.8, 28.8) | |||||
Abbreviations: CI = confidence interval; FoxP3 = forkhead box P3; IL-7R = interleukin-7 receptor; IL-12Rβ2 = interleukin-12 receptor β2; OS = overall survival (months).
Statistical analysis was performed by log-rank test; significant P-values (<0.05) are shown in bold type.
†
Stroma not applicable for this marker.
*
Adjusted for search of optimal cut-point.